Ann: Response to ASX Aware Query, page-8

What a complete load of BS !

From today's response ....
"LCT still has to decide if it will proceed with a regulatory submission to Medsafe or not, "

From the previous newsletter ...
"Complicated by proposed changes to the NZ Medicines Act, Medsafe has advised LCT that the small patient numbers from the Phase I/IIa and Phase IIb studies combined with the lack of compelling efficacy compared to the placebo means there is insufficient data at present to allow conditional approval under the current Medicines Act. This means it is not possible to treat paying patients in NZ, closing that avenue of potential revenue for the company. "

So in one newsletter, LCT say the Medsafe option is closed, followed by an ASX response saying they haven't decided whether or not to apply to Medsafe for registration !

Come on ASX ... this should be investigated further. I will be taking this up with them soon ....